Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 4/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718790 | 0.84 | SLC2A1 (0.36) | SLC2A1PIK3CAMTORDPP4SLC2A2 | |
| SCHEMBL17722607 | 0.82 | SLC2A1 (0.39) | SLC2A1DPP4SLC2A2LRRK2NOTUM | |
| SCHEMBL9946331 | 0.79 | SLC2A1 (0.35) | SLC2A1SLC2A2 | |
| SCHEMBL25159823 | 0.77 | ALDH1A1 (0.41) | SLC2A1 | |
| SCHEMBL23085724 | 0.74 | PIK3CD (0.41) | SLC2A1PIK3CAMTORDPP4SLC2A2 | |
| SCHEMBL20866529 | 0.73 | DPP4 (0.47) | DPP4NOTUM | |
| SCHEMBL4400829 | 0.71 | DPP4 (0.32) | DPP4NOTUM | |
| SCHEMBL19017302 | 0.70 | DPP4 (0.32) | DPP4NOTUM | |
| SCHEMBL26383543 | 0.69 | DPP4 (0.32) | DPP4NOTUM | |
| SCHEMBL9944473 | 0.69 | DPP4 (0.39) | DPP4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | SLC2A1 91/4885PIK3CA 1219/4885MTOR 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.